文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌单次24Gy机器人SBRT一日完成管理:PRO-FAST试验

Comprehensive one-day management of prostate cancer patients: PRO-FAST single-fraction ablative, urethral-sparing, HDR-like, robotic SBRT.
PubMed 文献 · Radiat Oncol · 2025-08-27

PRO-FAST是一项前瞻性、非随机、单中心试验,评估一日内完成全部流程的单次24Gy机器人SBRT(CyberKnife v.7)治疗前列腺癌(±精囊)的可行性、安全性和疗效,采用尿道保护HDR样技术和靶区追踪。第一阶段按Simon最优设计入组13例,若放疗结束后一个月内≥2例出现≥G3毒性(CTCAE v5.0)则终止,否则增至65例(另加5例至70例)。

要点

  • 单次24Gy机器人SBRT一日内完成全部流程,包括金标植入、影像、勾画、计划、质控和治疗。
  • 第一阶段13例按Simon最优设计,≥2例出现≥G3急性毒性则终止,否则扩至65例。
  • 主要终点为一个月急性毒性可行性,次要终点包括晚期毒性、生化控制和临床控制。

核心结论

  • 单次24Gy机器人SBRT一日完成全部流程在前列腺癌中尚需评估可行性、安全性和疗效。
  • 既往不同递送方式(不含追踪)的24Gy单次方案已显示非劣于5次SBRT。

研究设计与样本

  • 前瞻性、非随机、单中心试验,使用CyberKnife v.7机器人放射外科系统。
  • 第一阶段按Simon最优设计入组13例前列腺癌患者。
  • 若一个月内≥2例出现≥G3毒性则终止,否则追加52例至65例,另加5例至70例。

主要发现

  • 原文未报告结果数据。

关键数值与推荐

  • 单次剂量24Gy,照射前列腺(±精囊),采用尿道保护HDR样技术和靶区追踪。
  • 毒性终止标准:放疗结束后一个月内≥2例出现≥G3毒性(CTCAE v5.0)。
  • 主要终点为一个月急性毒性可行性;次要终点包括晚期毒性、生化控制和临床控制。

临床怎么用

  • 全部流程一日内完成,包括金标植入、影像采集、勾画、计划、剂量学质控和治疗。
  • 该模式可能方便远离放疗中心或有工作安排无法每日到院的患者。
  • 计划分析PSMA PET/CT在高危局限性疾病患者选择中的临床价值及与结局相关的影像组学特征。

局限性

  • 前瞻性、非随机、单中心设计。
  • 第一阶段样本量13例,最终计划70例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy (RT) is a standard curative treatment for prostate cancer (PCa) and there is growing evidence of the high efficacy of moderate and ultra-hypofractionated RT. Reducing treatment duration to one week or less is a major advance, but very few studies have explored single-fraction therapy. This study evaluates the feasibility, safety, and efficacy of single-fraction stereotactic body RT (SBRT) while delivering the entire procedure in one day, with a potentially high benefit in terms of patient comfort and therapy cost and logistics. METHODS: This prospective, non-randomized monocentric trial uses Robotic Radiosurgery (CyberKnife v.7 system) to deliver a single 24 Gy fraction to the prostate (± seminal vesicles) with a "urethral sparing HDR-like" technique, and target tracking. The first phase will enroll 13 PCa patients following Simon's optimal design. Treatment is to be stopped if ≥ 2 patients develop ≥ G3 toxicity (CTCAE v5.0) within a month from RT end; otherwise, 52 more patients will be added, totaling 65. To account for minimal drop-out, 5 extra patients will be enrolled, reaching 70. All procedures are performed in a single day, including fiducial implantation, imaging acquisition, contouring, planning, dosimetry quality control, and treatment. Apart from treatment feasibility in terms of one-month acute toxicity, secondary endpoints include late toxicity, biochemical and clinical control. DISCUSSION: Few others have investigated the 24 Gy single-fraction schedule using different delivery modalities (not including tracking), which has proved to be non-inferior to 5 fraction SBRT. Our approach aims to maintain (and possibly improve) the previously reported acute, subacute and late toxicity as well as disease control, adding evidence in favor of single-fraction delivery. Another significant goal of the study is the demonstration that all the complex treatment procedures can be safely delivered in a single day. This would be especially appealing for patients far from radiotherapy centers and those with work commitments not allowing daily hospital visits. The study of response to RT can also provide useful information about PCa radiobiology. Planned additional analyses may help in better assessing the clinical value of PSMA PET/CT in the selection of high-risk patients with true limited disease, and in identifying radiomic features associated to outcome. TRIAL REGISTRATION: The study was prospectively registered at clinicaltrials.gov (NCT05936736).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Fodor A, Giannini L, Torrisi M, et al. Comprehensive one-day management of prostate cancer patients: PRO-FAST single-fraction ablative, urethral-sparing, HDR-like, robotic SBRT. Radiat Oncol. 2025. PMID: 40866948. doi:10.1186/s13014-025-02713-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。